Investor Presentaiton

Performance: 2023 guidance builds on 2022's step change in delivery Remain firmly on track to deliver on 2026 outlooks 2022 performance (ex-pandemic¹) Sales¹ 10% growth Guidance: between 8 to 10% growth Adj. operating profit¹ 17% growth Guidance: between 15 to 17% growth Adj. earnings per share¹ 18% growth Guidance: growth around 1% below adj. operating profit COVID-19 solutions £2.4bn sales reduced overall adj. operating profit growth by around 3 percentage points Guidance: reduce overall adj. operating profit growth by around 4 percentage points 2023 guidance (ex-pandemic¹) Sales¹ Between 6% to 8% growth Adj. operating profit¹ Between 10% to 12% growth Adj. earnings per share¹ Between 12% to 15% growth COVID-19 solutions Not anticipating significant sales Expect this to reduce GSK sales growth by approximately 9% and reduce adj. operating profit growth by 6% to 7% Dividend: 56.5p per share; aligned to progressive dividend policy 1. Excluding COVID-19 solutions and at CER. Please also refer to page 2 of the fourth quarter 2022 results announcement. All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on pages 68 and 69 of our fourth quarter 2022 earnings release. See Appendix slide 35 for continuing operations basis of guidance. GSK 25 25

View entire presentation